Oxidative stress in Chronic Kidney Disease of unknown aetiology (CKDu) and the efficacy and safety of vitamin C and vitamin E in slowing the progression of early stages of CKDu in Sri Lanka. – A Double Blinded Placebo Controlled Randomized Clinical Trial

niversity of Colombo, Sri Lanka0 个研究点开始时间: 待定最近更新: 2024年8月20日

适应症

试验速览

暂无简介。

•1. Male and female patients aged between 18 and 45 years
•2. Diagnosed with stages 1-3 of chronic kidney disease of unknown origin, as determined by
•Albuminuria (ACR >30 mg/g)
•Decreased GFR
•Lower serum levels of liver enzymes
•Increased Beta-2 microglobulin (B2M) concentration
•Low serum bilirubin level

•1. Patients with renal insufficiency with a potentially reversible cause such as: malignant hypertension, urinary tract infection, hypercalcemia, drug-induced nephrotoxic effects systemic diseases such as connective-tissue diseases.
•2. Patients on drugs which are known to be used as antioxidants, such as Coenzyme Q10 (ubiquinone), Fish Oil (Omega – 3 polyunsaturated fatty acids), Vitamin B complex 100, Vitamin B12, Vitamin D3, Vitamin C, Vitamin E.
•3. Patients with Acute myocardial infarction or cerebrovascular accident in the previous 6 months.
•4. Patients with chronic diseases (e.g. bronchial asthma and chronic liver cell disease).
•5. Drug or alcohol abused Patients.
•6. Patients who are pregnant or breastfeeding.
•7. Patients who are not willing to participate in the study.
•8. Patients with Drug allergies.
•9. Patients with CKDu in stage 4 & 5.

发起方

niversity of Colombo, Sri Lanka